Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Down 41.3% in December

Aprea Therapeutics, Inc. (NASDAQ:APRE) saw a significant decline in short interest in December. As of December 15th, there was short interest totaling 34,578 shares, a decline of 41.3% from the November 30th total of 58,925 shares. Based on an average daily trading volume, of 100,933 shares, the short-interest ratio is currently 0.3 days. Currently, 0.6% of the shares of the stock are short sold. Currently, 0.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 100,933 shares, the short-interest ratio is currently 0.3 days.

Insider Buying and Selling at Aprea Therapeutics

In related news, Director Marc Duey purchased 21,459 shares of the business’s stock in a transaction that occurred on Wednesday, December 10th. The stock was acquired at an average cost of $1.17 per share, for a total transaction of $25,107.03. Following the completion of the purchase, the director owned 256,155 shares in the company, valued at approximately $299,701.35. This represents a 9.14% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 13.63% of the company’s stock.

Aprea Therapeutics Price Performance

NASDAQ APRE opened at $0.98 on Monday. The business has a fifty day moving average price of $1.18 and a two-hundred day moving average price of $1.47. The stock has a market capitalization of $6.85 million, a PE ratio of -0.46 and a beta of 1.23. Aprea Therapeutics has a fifty-two week low of $0.90 and a fifty-two week high of $5.00.

Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.36). Aprea Therapeutics had a negative net margin of 2,666.46% and a negative return on equity of 88.12%. The business had revenue of $0.00 million during the quarter. As a group, sell-side analysts expect that Aprea Therapeutics will post -2.55 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. HC Wainwright dropped their price objective on Aprea Therapeutics from $20.00 to $5.00 and set a “buy” rating for the company in a report on Thursday, December 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Aprea Therapeutics has an average rating of “Hold” and an average price target of $8.00.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.